An affiliate of Sun European Partners, LLP (“Sun European Partners”) has today announced the acquisition of NextPharma Technologies Holding Ltd. (“NextPharma”), a global provider of contract manufacturing, product development, clinical trials and logistics services to the pharmaceutical and biotechnology industry. Terms of the transaction were not disclosed.
Headquartered in Surrey, UK, NextPharma offers a range of services spanning the entire drug development, manufacturing and distribution supply chain. The company is a leading outsourcing partner to the pharmaceutical, biotech and healthcare industries with seven manufacturing facilities, seven product development centres and six temperature–controlled storage and distribution sites across Europe and the U.S.. NextPharma supports more than 200 customers including leading blue chip pharmaceutical and biotech companies.
Bill Wedlake, CEO of NextPharma commented: “The integrated outsourcing model offered by NextPharma helps improve client profitability by reducing both the cost and time to market of the product. This service increases client margins by reducing the number of supply chain providers and freeing up client resource to concentrate on their own key strategic strengths of research and marketing. We look forward to working with Sun European Partners to continue to grow the company and to expand into innovative new technologies and markets.”
Matthias Gundlach, Vice President of Sun European Partners said: “We are delighted by this acquisition. NextPharma is well positioned to benefit from the changing face of the drug industry, in particular using drug development and manufacturing outsourcing. It provides a good foundation from which to build the business organically and by acquisitions.”
Contact:
Fergus Wheeler
FTI Consulting
+44 (0) 20 3727 1522
suncapital.sc@fticonsulting.com